Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)

Laure Vincent

Montpellier, FR 
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Montpellier, FR 
OverviewLocationsClinical Research

Overview

Laure Vincent practices in Montpellier, France. Ms. Vincent is rated as an Experienced expert by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Multiple Myeloma, Chronic Graft Versus Host Disease (cGvHD), Light Chain Deposition Disease (LCDD), Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Transplant.

Her clinical research consists of co-authoring 79 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Monoclonal Gammopathy of Undetermined Significance (MGUS).

Gender
Female

Locations

Montpellier, France
Other Locations
Rennes, France
Poitiers, France
Bordeaux, France
CH Avignon
Avignon, France
Nantes, France
Clermont-ferrand, France
Besancon, France
Lyon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Identification of Genetic Factors Predisposing to Dysglobulinemia
Identification of Genetic Factors Predisposing to Dysglobulinemia
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Genetic
Study Phase: Not Applicable
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation
Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Drug
Study Drugs: Brentuximab, Etoposide, Carboplatin, Ifosfamide
Study Phase: Phase 1/Phase 2
MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis?
MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis?
Enrollment Status: Terminated
Publish Date: August 09, 2021
Intervention Type: Diagnostic test
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial
Enrollment Status: Completed
Publish Date: January 29, 2020
Intervention Type: Device
Study Phase: Phase 3
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: January 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

79 Total Publications

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.
Journal: Oncoimmunology
Published: July 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Vincent's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile